

IHS ILI Visits by Age, as % of Total, Week 45

Summary of ILI Surveillance in IHS:

- ILI definition, based on uploaded RPMS data: [influenza-specific ICD-9 code] or [measured temp > 100F and presence of at least 1 of 24 ILI ICD-9 codes].
- Of 498 IHS sites, 317 (63.7%) are reporting and have their data included in this report.
- Total ILI visits to IHS facilities reporting to IIAS have increased from a low of ~850/week (week 26) to a high of ~4300/week (week 39). Visits are currently running ~850/week (week 45).

- Overall, it appears that ILI % in IHS peaked at weeks 38-40. We will need to remain vigilant for a return of H1N1-related disease in IHS, and continue to work very hard to get our population and health care workers vaccinated, because it is unknown whether H1N1 will again emerge during the usual mid-winter influenza season.
- As in other populations in the United States, ILI is disproportionately affecting children in IHS.

Summary of response and mitigation efforts:

- No locations have reached surge capacity.
- Reports of shortages for seasonal flu vaccine are being reported.

Summary of H1N1 vaccine events:

- All IHS Areas are currently administering H1N1 vaccine. A total of 51,290 H1N1 vaccine doses have been administered by I/T/U facilities in these Areas. Figure 1 shows the cumulative number of H1N1 vaccine doses administered by I/T/U facilities. Table 1 includes a breakdown of H1N1 vaccine doses administered by age group.
- At least 69% of the H1N1 doses administered have been given to people in one of the following initial vaccine target groups (highlighted in red below): People 6 months – 24 years of age and People 25 – 64 years with a high risk medical condition. People in other groups who received vaccine may have fallen into one of the other target groups (Household contacts of <6 month olds, Healthcare Personnel).
- 2,612 doses of H1N1 vaccine have been administered to pregnant women
- 7,400 doses of H1N1 vaccine for healthcare personnel with direct patient contact employed in I/T/U facilities have been or soon will be distributed by the IHS National Supply Service Center (NSSC).
- As of Nov. 16th, 47.65 million doses of vaccine have been made available to states.
- The GlaxoSmithKline (GSK) H1N1 vaccine has been approved by FDA
- The CSL Biotherapies seasonal and H1N1 influenza vaccines can be used in children starting at 6 months of age.




Figure 1: Cumulative H1N1 Doses Administered

Table 1: Number of H1N1 Vaccine Doses Administered to Patients by Age Group

Number of H1N1 Vaccine Doses by Age Group	
< 5 years	9303
5-24 years	18,975
25-64 years high risk	7,329
25 – 64 no high risk condition	13,714
65+ years	1,969
Total Number of doses	51,290

Red denotes an initial target group for H1N1 vaccine. People in other groups who received vaccine may have fallen into one of the other target groups not included here - Household contacts of those < 6 months old and Healthcare Personnel.

Key Points:

- Influenza-like illness in IHS is declining.
- Vaccination for patients and providers is underway and increasing

Key Community Messaging Points:

- Please visit <u>www.ihs.gov/H1N1</u> for information about H1N1 activities and Indian Country.
- Take these steps to stay healthy: <u>http://www.flu.gov/individualfamily/prevention/index.html</u>
- Information regarding the different types of H1N1 vaccine: http://www.flu.gov/individualfamily/vaccination/index.html
- Questions and Answers regarding vaccine safety: <u>http://www.cdc.gov/h1n1flu/vaccination/vaccine_safety_qa.htm</u>

Other announcements:

• None